The Antiviral Activity of the Sage-Leaved Rockrose Extract (Cistus Salviifolius) Against the Influenza Virus
Abstract
A study of the protective activity of the Sage-leaved Rockrose extract (Cistus salviifolius) and the biologically active additive Forcys in the MDCK cell culture and on the model of lethal influenza pneumonia in white mice was carried out.The studied extract inhibited the reproduction of all used influenza viruses. The most sensitive to it were the viruses A/California/07/09 (H1N1)pdm09, A/mallard/Pennsylvania/10218/84 (H5N2), and A/Vladivostok/02/09 (H1N1). The IC50 values of the listed viruses were 0.5, 0.5, and 0.4 μg/ml, and the selectivity indexes were 382, 382, and 478, respectively, which is characteristic for preparations with high antiviral activity. Type B influenza viruses were less sensitive to the extract.The inhibitory activity of the extract did not depend on the susceptibility or resistance of the viruses to the anti-influenza drugs used, oseltamivir and rimantadine. The reduction in specific mortality with influenza pneumonia in animals was 40% compared with the placebo group.The use of the biologically active supplement Forcys did not affect the infectious activity of the influenza virus in the tissues of the animals lungs and led to a moderate limitation of the degree of damage to lung tissue. The maximum effectiveness of the biologically active supplement Forcys was achieved with the therapeutic and prophylactic regimens of its use.
About the Authors
I. N. Lavrentieva
Saint-Petersburg Pasteur Institute
Russian Federation
Russian Federation
L. P. Sukhobaevskaya
Saint-Petersburg Pasteur Institute
Russian Federation
Russian Federation
V. V. Zarubayev
Saint-Petersburg Pasteur Institute
Russian Federation
Russian Federation
References
1. Ahmed R., Oldstone M.B., Palese P. Protective immunity and susceptibility to infectious diseases: lessons from the 1918 influenza pandemic. Nat Immunol 2007; 8:1188-1193.
2. Scholtissek C, Quack G., Klenk H.D., Webster R.G. How to overcome resistance of influenza A viruses against adamantane derivatives. Antiviral Res 1998; 37: 83-95.
3. Fiore A.E., Fry A., Shay D. et al. Antiviral agents for the treatment and chemoprophylaxis of influenza. Recomm Rep 2011; 60:1: 1-26.
4. Kiso M., Takahashi K., Sakai-Tagawa Y. et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci USA 2010; 107: 882-887.
5. Sleeman K., Mishin V.P., Deyde V.M. et al. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob Agents Chemother 2010; 54: 2517-2524.
6. Smee D.F., Hurst B.L., Wong M.H. et al. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob Agents Chemother 2010; 54: 126-133.
7. Furuta Y., Takahashi K., Shiraki K. et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 2009; 82: 95-102.
8. Pizzorno A., Abed Y., Boivin G. Influenza drug resistance. Semin Respir Crit Care Med 2011; 32: 409-422.
9. Hauge S.H., Dudman S., Borgen K. et al. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis 2009; 15: 155-162.
10. Thorlund K., Awad T., Boivin G., Thabane L. Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis 2011; 11: 134.
11. Mosmann Т. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 1-2: 55-63.
12. Reed L.J., Muench H. A simple method of estimating fifty percent end-points. Am J Hyg 1938; 27: 493-497.
13. Papaefthimiou D., Papanikolaou A., Falara V. et al. Genus Cistus: a model for exploring labdane-type diterpenes’ biosynthesis and a natural source of high value products with biological, aromatic, and pharmacological properties. Front Chem 2014; 2: 35.
14. Conti C., Mastromarino P., Goldoni P. et al. Synthesis and anti-rhinovirus properties of fluoro-substituted flavonoids. Antivir Chem Chemother 2005; 16: 267-276.
15. Iranshahi M., Rezaee R., Parhiz H. et al. Protective effects of flavonoids against microbes and toxins: The cases of hesperidin and hesperetin. Life Sci 2015; 137: 125-132.
16. Tait S., Salvati A.L., Desideri N., Fiore L. Antiviral activity of substituted homoisoflavonoids on enteroviruses. Antiviral Res 2006; 72: 252-255.
17. Desideri N., Conti C., Sestili I. et al. In vitro evaluation of the anti-picornavirus activities of new synthetic flavonoids. Antivir Chem Chemother 1995; 6: 298-306.
18. Desideri N., Olivieri S., Stein M.L. et al. Synthesis and anti-picornavirus activity of homo-isoflavonoids. Antivir Chem Chemother 1997; 8: 545- 555.
19. Ehrhardt C., Hrincius E.R., Korte V. et al. A polyphenol rich plant extract, CYSTUS052, exerts anti influenza virus activity in cell culture without toxic side effects or the tendency to induce viral resistance. Antiviral Res 2007; 76: 1: 338-347.
20. Droebner K,, Ehrhardt C,, Poetter A, et al. CYSTUS052, a polyphenol-rich plant extract, exerts anti-influenza virus activity in mice. Antiviral Res 2007; 76: 1: 1-10.
21. Kalus U., Grigorov A., Kadecki O. et al. Cistus incanus (CYSTUS052) for treating patients with infection of the upper respiratory tract. A prospective, randomised, placebo-controlled clinical study. Antiviral Res 2009; 84: 3: 267-271
22. Manach C., Scalbert A., Morand C. et al. Polyphenols: food sources and bioavailability. Am J Clin Nutr 2004; 79: 727-747
Review
For citations:
Lavrentieva I.N., Sukhobaevskaya L.P., Zarubayev V.V. The Antiviral Activity of the Sage-Leaved Rockrose Extract (Cistus Salviifolius) Against the Influenza Virus. Antibiot Khimioter = Antibiotics and Chemotherapy. 2017;62(5-6):12-20. (In Russ.)
Views:
1711
Email this article 